Margaret Koziel, MD

Chief Medical Officer

Margaret Koziel, M.D., brings 16 years of drug development and executive leadership experience to Boston Pharmaceuticals. She previously was CMO at Innoviva, a commercial stage company focused on critical care and infectious disease. Prior to Innoviva, she was CMO at Axcella Therapeutics. She joined Axcella as program head for studies in metabolic liver disease (MASH), and assumed increasing responsibilities for oversight of clinical programs before her promotion to CMO. Previous to that, she held positions of increasing responsibility at Kaleido Biosciences, Vertex and the Novartis Institute for Biomedical Sciences, and has worked across the full spectrum of clinical development from target selection through phase IV studies. She has focused on hepatology and infectious disease for most of her career, although she has also worked on oncology, rare diseases, Long COVID and immunology.

Dr. Koziel has also held positions in academia, as a Professor and Assistant Vice Provost for Clinical Research at the University of Massachusetts Medical School; and as a staff physician the Beth Israel Deaconess medical center and an Associate Professor of Medicine at Harvard Medical School Her research interest was the immune response to hepatitis C virus, as well as advancing the clinical care of people with HIV. While at the Beth Israel Deaconess, she received numerous awards for her research, including being named as a Fellow of the Infectious Disease Society of America and a member of the American Society of Clinical Investigation. Dr. Koziel has published over 90 papers and chapters, including in journals such as the New England Journal of Medicine and The Journal of Clinical Investigation, and has served as an associate editor and reviewer for numerous journals. She obtained her BA and MD from Dartmouth College, and her postgraduate medical training at the New England Deaconess Hospital and Massachusetts General Hospital.